摘要
目的探究慢性胰腺炎合并消化不良患者在治疗过程中应用复方阿嗪米特联合盐酸伊托必利干预的价值。方法方便选取该院消化内科慢性胰腺炎消化不良患者100例,选取时间为2016年3月—2016年8月,根据患者治疗方案的不同进行分组,其中对照组仅接受盐酸伊托必利治疗,实验组则接受盐酸伊托必利与复方阿嗪米特联合治疗,对比两组慢性胰腺炎消化不良患者治疗后症状评分、不良反应等的差异性。结果实验组症状评分(腹痛、腹胀、食欲不振、嗳气、早饱)分别为(0.71±0.66)分、(0.75±0.58)分、(0.80±0.11)分、(1.02±0.29)分、(0.41±0.05)分均明显低于对照组(P<0.05);且实验组非腹胀痛症状积分下降值、生活满意度积分上升值、腹胀痛严重程度积分下降值分别为(13.41±5.30)分、(7.81±4.12)分及(5.41±2.82)分,均明显优于对照组(P<0.05);实验组不良反应发生率(10.00%)与对照组不良反应的几率(8.00%)相比,差异无统计学意义(P>0.05)。结论采取复方阿嗪米特与盐酸伊托必利联合治疗慢性胰腺炎消化不良的效果显著,且具有较高的安全性。
Objective To study the value of azintamide and itopride hydrochloride in patients with chronic Pancreatitis with dyspepsia.Methods 100 cases of patients with chronic pancreatitis with dyspepsia in our hospital from March 30,2016 to August 2016 were commodiously selected and divided into two groups according to different treatment plans,the control group were treated with simple itopride hydrochloride,while the experimental group were treated with azintamide and itopride hydrochloride,and the symptom score and adverse reactions of patients were compared between the two groups.Results The symptom scores(abdominal pain,abdominal distension,loss of appetite,belching,early satiety)in the experimental groups were respectively(0.71±0.66)points,(0.75±0.58)points,(0.80±0.11)points,(1.02±0.29)points,(0.41±0.05)points,which were obviously lower than those in the control group,P<0.05,and the decrease value of non-abdominal distention integral,increase value of life satisfactory degree integral and severity of abdominal distention pain decrease value in the experimental group were respectively(13.41±5.30)points,(7.81±4.12)points and(5.41±2.82)points,which were obviously better than those in the control group(P<0.05),and the difference in the occurrence probability of adverse reactions between the experimental group and the control group was not obvious(10.00%vs 8.00%),difference are statistically significant(P>0.05).Conclusion The effect of azintamide and itopride hydrochloride in patients with chronic Pancreatitis with dyspepsia is obvious with high safety.
作者
张建华
ZHANG Jian-hua(Digestive System Department,Juancheng People’s Hospital,Juancheng,Shandong Province,274600 China)
出处
《中外医疗》
2018年第2期118-120,共3页
China & Foreign Medical Treatment